Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BIOMARIN PHARMACEUTICAL INC.

(BMRN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/11/2021 06/14/2021 06/15/2021 06/16/2021 06/17/2021 Date
82.07(c) 82.48(c) 81.96(c) 82.48(c) 82.98(c) Last
745 283 634 597 557 669 1 030 805 827 370 Volume
-1.91% +0.50% -0.63% +0.63% +0.61% Change
More quotes
Financials (USD)
Sales 2021 1 823 M - -
Net income 2021 -101 M - -
Net cash position 2021 249 M - -
P/E ratio 2021 -163x
Yield 2021 -
Sales 2022 2 206 M - -
Net income 2022 159 M - -
Net cash position 2022 538 M - -
P/E ratio 2022 93,0x
Yield 2022 -
Capitalization 15 164 M 15 164 M -
EV / Sales 2021 8,18x
EV / Sales 2022 6,63x
Nbr of Employees 3 059
Free-Float 99,4%
More Financials
Company
BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine... 
Sector
Pharmaceuticals
Calendar
07/17Presentation
More about the company
Ratings of BioMarin Pharmaceutical Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about BIOMARIN PHARMACEUTICAL INC.
06/15BIOMARIN PHARMACEUTICAL  : to Participate in the Virtual BofA Securities 2021 Na..
PR
06/04BIOMARIN PHARMACEUTICAL  : Baird Starts BioMarin Pharmaceutical at Outperform wi..
MT
06/02BIOMARIN PHARMACEUTICAL  : Amendment to Credit Agreement (Form 8-K)
PU
06/02BIOMARIN PHARMACEUTICAL INC  : Entry into a Material Definitive Agreement, Creat..
AQ
06/01BIOMARIN PHARMACEUTICAL INC  : Change in Directors or Principal Officers, Submis..
AQ
05/27BIOMARIN PHARMACEUTICAL  : to Participate in Two Upcoming Virtual Investor Confe..
PR
05/24BIOMARIN PHARMACEUTICAL  : Gets Approval for Accelerated Assessment of Severe He..
MT
05/24BIOMARIN PHARMACEUTICAL  : European Medicines Agency Grants BioMarin's Request f..
PR
05/20BIOMARIN PHARMACEUTICAL  : Provides Highlights of 5 Years of Clinical Data from ..
AQ
05/19BIOMARIN PHARMACEUTICAL  : Provides Highlights of 5 Years of Clinical Data from ..
PR
05/18BIOMARIN PHARMACEUTICAL  : to Participate in Two Upcoming Virtual Investor Confe..
PR
05/13BIOMARIN PHARMACEUTICAL  : Announces 6 Presentations at American Society of Gene..
AQ
05/05INSIDER TRENDS : BioMarin Pharmaceuticals Insider Awarded Shares Uses Portion to..
MT
05/03BIOMARIN PHARMACEUTICAL  : to Participate in Two Upcoming Virtual Investor Confe..
PR
04/30BIOMARIN PHARMACEUTICAL  : Management's Discussion and Analysis of Financial Con..
AQ
More news
News in other languages on BIOMARIN PHARMACEUTICAL INC.
2020Aktien New York Schluss: Dow geht Puste aus nach Rekord - Nasdaq steigt
2020Aktien New York: Dow geht nach Rekordhoch die Puste aus - Nasdaq stark
2020Aktien New York Schluss: Dow und Nasdaq fallen trotz Apple-Meilenstein
2020Aktien New York: Dow und Nasdaq verhalten im Plus - Apple mit Meilenstein
2020Aktien New York: Dow am Mittwoch gefragter als der Nasdaq 100
More news
Analyst Recommendations on BIOMARIN PHARMACEUTICAL INC.
More recommendations
Chart BIOMARIN PHARMACEUTICAL INC.
Duration : Period :
BioMarin Pharmaceutical Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOMARIN PHARMACEUTICAL INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 23
Average target price 108,32 $
Last Close Price 82,98 $
Spread / Highest target 94,0%
Spread / Average Target 30,5%
Spread / Lowest Target -1,18%
EPS Revisions
Managers and Directors
NameTitle
Jean-Jacques Bienaimé Chairman & Chief Executive Officer
Brian R. Mueller Chief Financial Officer & Executive Vice President
Henry J. Fuchs President-Worldwide Research & Development
Eduardo E. Von Pervieux Chief Information Officer
Geoffrey M. Nichol Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
BIOMARIN PHARMACEUTICAL INC.-5.37%15 164
CSL LIMITED6.72%103 997
WUXI BIOLOGICS (CAYMAN) INC.17.51%65 667
BIOGEN INC.56.63%57 741
SAMSUNG BIOLOGICS CO.,LTD.0.85%48 638
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.20.95%44 390